RBM10 and neoplasm: Given that activation of the JAK1 and JAK2 pathways has been demonstrated to inhibit tumour cell susceptibility to NK cells by upregulating PD-L1 expression 39, we further investigated the activation status of the JAK-STAT pathway in RBM10-knockdown pancreatic cancer cells.